Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 November 2013Website:
http://www.karyopharm.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:39:06 GMTDividend
Analysts recommendations
Institutional Ownership
KPTI Latest News
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of XPOVIO® in China. - Results from the registrational SEARCH study in China showed that the overall response rate (ORR) among the 60 Chinese patients treated with XPOVIO® met the study's prespecified primary endpoint.
Karyopharm Therapeutics Inc. is showcasing selinexor in 7 presentations at ASCO and investigating its potential in myelofibrosis through two upcoming trials. Despite facing financial challenges, positive results in pivotal trials could greatly impact selinexor's future success.
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.43 per share a year ago.
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - CFO Conference Call Participants Maury Raycroft - Jefferies Colleen Kusy - Baird Operator Good morning. My name is Guru and I will be your conference operator today.
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.62 per share a year ago.
Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The Food and Drug Administration (FDA) has granted fast-track designation to the development of selinexor.
Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning.
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.53 per share a year ago.
What type of business is Karyopharm Therapeutics?
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
What sector is Karyopharm Therapeutics in?
Karyopharm Therapeutics is in the Healthcare sector
What industry is Karyopharm Therapeutics in?
Karyopharm Therapeutics is in the Biotechnology industry
What country is Karyopharm Therapeutics from?
Karyopharm Therapeutics is headquartered in United States
When did Karyopharm Therapeutics go public?
Karyopharm Therapeutics initial public offering (IPO) was on 06 November 2013
What is Karyopharm Therapeutics website?
https://www.karyopharm.com
Is Karyopharm Therapeutics in the S&P 500?
No, Karyopharm Therapeutics is not included in the S&P 500 index
Is Karyopharm Therapeutics in the NASDAQ 100?
No, Karyopharm Therapeutics is not included in the NASDAQ 100 index
Is Karyopharm Therapeutics in the Dow Jones?
No, Karyopharm Therapeutics is not included in the Dow Jones index
When does Karyopharm Therapeutics report earnings?
The next expected earnings date for Karyopharm Therapeutics is 02 August 2024